Shanghai Haihe Biopharma Co., Ltd. announced that it has entered into an financing agreement and received $146.6 million in its series B round of funding led by HG Healthcare Venture Capital Chengdu Partnership Enterprise (Limited Partnership), a fund managed by Beijing HuaGai Healthcare Investment Management Co., Ltd. on February 11, 2019. The transaction also included participation from CSPC Pharmaceutical Group Limited (SEHK:1093), DAE HWA Pharmaceutical Co., Ltd. (KOSDAQ:A067080), Hillhouse Capital Management, Ltd., Boyuan Capital Limited, Atlas Capital, Yingke Innovation Asset Management Co., Ltd., Elite Capital, CAS Venture Capital Management Co., Ltd.